Matthew M Riggs (Matthew Riggs)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Venues

British journal of clinical pharmacology

Clinical pharmacology and therapeutics

Pharmaceutics

Metrum Research Group

University of Connecticut (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Metrum Research Group May 25 2005

United States

Chief Science Officer

Education History

University of Connecticut Sep 01 1994 - Dec 15 1999

United States

PHD :: School of Pharmacy

University of Connecticut Sep 01 1989 - May 07 1994

United States

BSC :: School of Pharmacy

Publications

Rena J Eudy-Byrne, Matthew M Riggs, Amale Hawi, Thomas Sciascia, Shashank Rohatagi
A population pharmacokinetic-pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis. British journal of clinical pharmacology (2023)
Rena J Eudy-Byrne, Matthew M Riggs, Amale Hawi, Thomas Sciascia, Shashank Rohatagi
A Population Pharmacokinetic-Pharmacodynamic Model Evaluating Efficacy of Nalbuphine Extended-Release in Patients with Prurigo Nodularis. British journal of clinical pharmacology (2023)
Oliver Pohl, Kyle Baron, Matthew M Riggs, Jonathan French, Ramon Garcia, Jean-Pierre Gotteland
A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis. British journal of clinical pharmacology 88 (5) (2022)
Katherine Kay, Justin Goodwin, Hanna Ehrlich, Joyce Ou, Tracey Freeman, Kaicheng Wang, Fangyong Li, Martina Wade, Jonathan French, Liusheng Huang, Francesca Aweeka, Norah Mwebaza, Richard Kajubi, Matthew M Riggs, Ana Ruiz-Garcia, Sunil Parikh
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical pharmacology and therapeutics (2022)
Curtis K Johnston, Rena J Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, Matthew M Riggs, Karl-Heinz Liesenfeld
A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes. Pharmaceutics 13 (4) (2021)
Matthew M Riggs, Jeffrey K Aronson
Pharmacometrics and systems pharmacology for metabolic bone diseases. British journal of clinical pharmacology 85 (6) (2019)

Matthew M Riggs.css-eqlu8i{font-size:small;padding-left:4px;} (Matthew Riggs)

Publication Activity (10 Years)

Top Topics

Top Venues

Matthew M Riggs (Matthew Riggs)